A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1

Trial ID # NCT02799095; ARTISTRY-1
Phase I/II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Nemvaleukin alfa, Pembrolizumab
Eligible Participant

Advanced solid tumors

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, DoR, evaluated per RECIST


ALKS 4230: 36 patients, median 3 prior therapies (1-8), 1 ovarian
27 evaluable: DCR: 51.9% (14SD)

ALKS 4230+Pem: 14 ovarian, median 5 prior therapies (2-11)
ORR: 28.6% (1CR, 2PR, 1uPR - all responders Pt-R, BRCA WT, checkpoint inhibitor naive)
DCR: 71.4%% (1CR, 2PR, 1uPR, 6SD)
DoR: 12.3 months


Pembrolizumab with Nemvaleukin alfa (ALKS 4230) is well tolerated with encouraging clinical benefit


Boni V et al. ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. J Clin Oncol (2021) 39 (suppl 15; abstr 2513)

Boni V et al. Poster

Slide from SGO 2022 presentation; scientific plenary III, abstract 229

Vaishampayan UN et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J Clin Oncol 40, 2022 (suppl 16; abstr 2500)

Vaishampayan UN et al. Slide from presentation

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.